alternative / integrative
N-Acetylcysteine (NAC) for MPN
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-03-10 — An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms: Phase I/II dose-finding trial underway evaluating the optimal dose of N-acetylcysteine in MPN patients, representing the first formal clinical trial of NAC in this population (evidence: trial-early). (novelty: 3)
Open questions
Related
Contributing findings
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
10-mar-2026
novelty 3
per-area 3
introduces